Great pull Axsome is doing big things in the psychiatry space -- Auvelity will likely reach blockbuster status in the next ~ 2 years, and solriamfetol (Sunosi) has big potential for sales growth too:

I have much more to say on this, so stay tuned. It's super apparent to just about everyone at this point that only a very, very small portion of the projects being pushed in DeSci have any potential imminent commercial viability. I see this as one of the few exceptions

Whether the markets are bearish or bullish, we’re going to stay working hard.

DeSciWorld Namkhai Ferdaña I agree with Namkhai Ferdaña here. I understand the wariness of the “commercialization of science” to an extent. But I would push back and say that the goal of DeSci should be to build paradigms and frameworks that allow for better alignment of commercial and public good interests.

Unfortunately, I was not able to make it out on this go-around. But Andreas Melhede bio/acc Kyle (wkyleg.eth) will be going over some big things. Stay tuned!

Imagine getting paid for safely sharing your health data with researchers onchain. That's ZORP. Private. Secure. Rewarding. We're building the bridge between patients and research. Learn more ↓

Hot Off the Press: Remarkable discovery reveals mutations in RNU2-2 gene cause severe neurodevelopmental disorder with epilepsy. This changes our understanding of genetic disorders. Here’s why this is important… 1/13

We kicked off Day 1 at Decentralised Science (DeSci) London and the energy is electric. Meeting the faces behind pioneering projects hits different in person. Running a Mental Health x Web3 workshop tomorrow. What burning questions should we tackle? The floor is yours!

Biotech analysts studied 229 preclinical asset deals signed between '10–'15 to see which ones reached late stage clinical development & resulted in revenue for licensors h/t Recon Strategy. Assets without a specified target rarely progressed into the clinic which suggests these

The capability of the Elata Biosciences aggregator continues to impress me. As CNS markets continue to grow, it'll be a key tool for all types of market participants. Important read for public capital market neuroscience investors btw: news.elata.bio/?category=indu…

Btw we have used literally everything at Elata Biosciences for neuroscience insights. We've used Bloomberg/Refintiv, preprints, AUTM feeds, Clarivate, Preqin, etc, and have yet to encounter something with this level of neuroscience depth. Investors can use it or get left behind.

$MRK CEO signals wants and NEEDS to do deals, even in uncertain macro environment, willing to be aggressive for value. 2025 could get exciting for Biotech

It's here! We just finished our first ElataEEG prototype - an open-source brain scanner for $300 instead of $20k! Clean interface, research-grade quality, and plugin support. We built this in months, not years. What would you study if brain research was 98.5% cheaper?

Unfortunately, YTD performance is still negative. $XBI is bullish long-term though due to the immense issues downstream of the 5 year patent cliffs in pharma though. We will see a lot of transactions over the next 5 years, especially in the neuroscience space.

When you look at where VC money has been going in the last ~ 10 years, most of it has gone to drug discovery capability. Yet drugs fail at a higher rate than ever before. This is just one (of many) examples to validate the point being made by David K. Yang

Amazing work by Kyle (wkyleg.eth) and the engineering team Elata Biosciences to move the needle in open source neuropsychiatry. We are entering a new paradigm in biomedicine -- one where real neuroscience growth is feasible.

New fascinating study reveals link between mitochondrial DNA and bipolar disorder. This is a major breakthrough in understanding bipolar disorder's biological roots showing specific mitochondrial DNA mutations may be key drivers. Here's why this matters... 🧵 1/13

CEO announcing new feature vs. engineers saying it's not ready

The three main funders in biotech/pharma are: Gov'ts, venture (early-stage private) and institutional (late-stage private). IMO, it makes most sense for venture to fund pre-clinical/early clinical NMEs, institutional funds late stage, and then the gov fills the gaps and

Even in a polarized world, it’s pretty hard to hate on this.